Mikkael Sekeres, MD details a clinical presentation of a 74-year-old man diagnosed 9 months ago with LR-MDS with a hemoglobin of 7.8 g/dL.
First in Class Telomerase Inhibitor (Imetelstat) for Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Dr Sekeres discusses when to start therapy for a patient who has lower-risk MDS with amnesia.
Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with imetelstat.
Dr Sekeres discusses treatment goals for a patient with lower-risk MDS.
Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with luspatercept.
Dr Sekeres discusses key takeaways for optimizing anemia management in lower-risk MDS, as well as where he sees the most significant unmet needs.
Dr Sekeres discusses how he approaches second-line therapy selection in ESA-refractory, transfusion-dependent lower-risk MDS (LR-MDS) patients, specifically with lenalidomide.
Dr Sekeres shares his thoughts about the choice between an EMA and a telomerase inhibitor in the RS-negative patient.
Dr Sekeres discusses the adverse event profile and AE management of imetelstat.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
4
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
5